Topical timolol in dermatology: infantile haemangiomas and beyond

M. Alzaid, A. Al-Naseem, F. Al-Niaimi, F. R. Ali*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
153 Downloads (Pure)


Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.

Original languageEnglish
JournalClinical and Experimental Dermatology
Issue number5
Pages (from-to)819-832
Number of pages14
Publication statusPublished - May 2022

Bibliographical note

© 2021 British Association of Dermatologists.


Dive into the research topics of 'Topical timolol in dermatology: infantile haemangiomas and beyond'. Together they form a unique fingerprint.

Cite this